Maraviroc

Nature Reviews Drug Discovery

Volumn 7, Issue 1, 2008, Pages 15-16

  Kuritzkes, Daniel ^a   Kar, Santwana ^b   Kirkpatrick, Peter ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b IQVIA   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; DARUNAVIR; EFAVIRENZ; ENFUVIRTIDE; LAMIVUDINE; MARAVIROC; PLACEBO; TIPRANAVIR; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG APPROVAL; DRUG DETERMINATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESISTANCE; DRUG SAFETY; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LYMPHOCYTE COUNT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS RESISTANCE;

EID: 37749011180     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2490     Document Type: Article

References (10)

1. Flexner, C. HIV drug development: The next 25 years. Nature Rev. Drug Disc. 6, 959-966 (2007).
2. Tsibris, A. M. & Kuritzkes, D. R. Chemokine antagonists as therapeutics: Focus on HIV- 1. Annu. Rev. Med. 58, 445-459 (2007).
3. Darr, P. et al. Maraviroc (UK-427,857), a potent, orally bicavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49. 4721-4732 (2005).
4. Food and Drug Administration. FDA labelling information [online], http://www.fda.gov/cder/foi/labcl/2007/022128lbl.pdf. (2007).
5. Fatkenheuer, G. et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nature Med. 11, 1170-1172 (2005).
6. European Medicines Agency. European Public Assessment Report [online], (2007).
7. Clumeck, N. et al. A multicenter, randomized, double-blind, comparative rial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment of antiretroviral naive subjects infected with R5 HIV- 1: Week 48 results of the MERIT study. 4th IAS Conference on HIV Pathogeneis, Treatment and Prevention, Sydney. Australia, July 22-25 [Abstract WESS104]. IAS2007.org web site [online], (2007).
8. Reeves, J. D. et al. Enhancements to the Trofile HIV coreceptor tropism assay enable reliable detection of CXCR4-using subpopulations at less than 1%. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 17-20 [Abstract H-1026]. American Society of Microbiology web site [online], (2007)
9. Wilkin, T.A. et al. Chemokine coreceptor tropism among antiretroviral-experienced patients screening for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group 5211. Clin. Infect. Dis. 44, 591-595 (2007).
10. + cell depletion and progression to AIDS. Ann. Intern. Med. 118, 681-688 (1993).